Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright 26^th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.

Read more at globenewswire.com